Akums Drugs and Pharmaceuticals (NSE:AKUMS) ROCE %: 13.34% (As of Mar. 2026)


NSE:AKUMS Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
48 GF Score
Price ₹626.80
! 7 Warning Signs
View Full Analysis

What is Akums Drugs and Pharmaceuticals ROCE %?

Akums Drugs and Pharmaceuticals NSE:AKUMS -1.67% 48 ROCE % is 13.34% as of Mar. 2026. GuruFocus rates NSE:AKUMS with a GF Score™ of 48/100. The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Akums Drugs and Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 13.34%.

Akums Drugs and Pharmaceuticals  (NSE:AKUMS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Akums Drugs and Pharmaceuticals ROCE % Related Terms

Akums Drugs and Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Akums Drugs and Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals ROCE % Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial -10.45 10.34 0.23 13.60 12.43

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.90 14.15 7.91 11.40 13.34
NSE:AKUMS
48GF Score
Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akums Drugs and Pharmaceuticals ROCE % Calculation

Akums Drugs and Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=4707.23/( ( (41134.42 - 8937.47) + (54469.65 - 10947.57) )/ 2 )
=4707.23/( (32196.95+43522.08)/ 2 )
=4707.23/37859.515
=12.43 %

Akums Drugs and Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=5804.32/( ( (0 - 0) + (54469.65 - 10947.57) )/ 1 )
=5804.32/( ( 0 + 43522.08 )/ 1 )
=5804.32/43522.08
=13.34 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.34% mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a ROCE % of 13.34% as of Mar. 2026.
Is Akums Drugs and Pharmaceuticals' ROCE % too high?
Akums Drugs and Pharmaceuticals' current ROCE % is 13.34%. The Drug Manufacturers industry median ROCE % is 7.02. Akums Drugs and Pharmaceuticals' value of 13.34% is 90% above this industry median. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' ROCE % compare to ZTS and UTHR?
Akums Drugs and Pharmaceuticals' ROCE % of 13.34% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.02. Akums Drugs and Pharmaceuticals' value of 13.34% is 90% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.02, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current ROCE % of 13.34% is 90% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current ROCE % is 13.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current ROCE % of 13.34%. The current ROCE % is 13.34% and 90% above the Drug Manufacturers industry median of 7.02. Akums Drugs and Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current ROCE % is 13.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akums Drugs and Pharmaceuticals Business Description

Other Exchanges 544222:India
Address Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
48GF Score

Get the complete analysis for NSE:AKUMS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹626.80
Price